This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Answering the question post #29 raises rather than the one it answers.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
The conclusion is tentative; the arithmetic underneath it is not.
The arithmetic in post #29 is right; the assumption feeding it is the part to check.
Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.
I would put this at better than even and not much better.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
Narrowing post #33, because the general version has more than one answer.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
The short version is the first sentence; the rest is why.
Adding a small correction to the Tirzepatide in type 2 diabetes summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
Worth one more sentence than it usually gets.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
Useful. I had the fact and not the reason, which turns out to be the important half.
I had written a reply contradicting post #40 and deleted it. Here is what survived.
A note on how Tirzepatide in type 2 diabetes gets discussed rather than on Tirzepatide in type 2 diabetes itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
On post #44 — agreed on the reasoning, with one qualification.
My position on Tirzepatide in type 2 diabetes is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Post #46 is right about the mechanism and I think understates the practical bit.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
Written from notes rather than memory, which is why the numbers are specific.
Where the Tirzepatide in type 2 diabetes discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
Narrowing post #46, because the general version has more than one answer.
Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.
It is worth stating the boring hypothesis before the interesting one.
What I can speak to on Tirzepatide in type 2 diabetes is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Where I have landed on Tirzepatide in type 2 diabetes, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
Not a strong opinion, just a consistent one.
Post #51 is right about the mechanism and I think understates the practical bit.
SURPASS-2's comparator choice is the criticism that survives. Semaglutide 1.0 mg was the licensed diabetes dose at the time and it was not the highest dose available in the class, so the trial answers a narrower question than the headline implies.
If anyone has run this properly I would rather read that than my own guess.
Post #51 and I disagree about the size of the effect, not about the direction.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.
Adding the measurement that post #59 says would settle it.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.